Certara, Inc. (CERT)

Market Cap	1.33B
Revenue (ttm)	415.55M
Net Income (ttm)	10.88M
Shares Out	159.27M
EPS (ttm)	0.07
PE Ratio	123.15
Forward PE	16.09
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,752,913
Open	8.23
Previous Close	8.41
Day's Range	8.18 - 8.45
52-Week Range	8.13 - 15.69
Beta	1.45
Analysts	Buy
Price Target	14.50 (+74.07%)
Earnings Date	Nov 6, 2025

About CERT

Certara, Inc., together with its subsidiaries, provides technology-enabled services and software products for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access. It offers solutions for model-informed drug development, as well as biosimulation solutions to predict pharmacokinetics and pharmacodynamics; Simcyp simulator, a mechanistic biosimulation platform for physiologically based pharmacokinetic simulation; Simcyp Discovery for scientists working on pre-investigational new drug and tr...

• Industry: Health Information Services
• Sector: Healthcare
• IPO Date: Dec 11, 2020
• Employees: 1,546
• Stock Exchange: NASDAQ
• Ticker Symbol: CERT
• Website: https://www.certara.com

Financial Performance

In 2024, Certara's revenue was $385.15 million, an increase of 8.70% compared to the previous year's $354.34 million. Losses were -$12.05 million, -78.23% less than in 2023.

Analyst Summary

According to 9 analysts, the average rating for CERT stock is "Buy." The 12-month stock price target is $14.5, which is an increase of 74.07% from the latest price.

Price Target

$14.5

(74.07% upside)

Analyst Consensus: Buy